May 11, 2017

PET/CT bests contrast CT at monitoring metastatic breast cancers

PET/CT is superior to contrast-enhanced CT when it comes to predicting both progression-free and disease-specific survival in patients with metastatic breast cancer, according to a study published online May 1 in the European Journal of Nuclear Medicine and Molecular Imaging. {read more here}